Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AKCEA TTR LRx

Drug Profile

AKCEA TTR LRx

Alternative Names: AKCEA-TTR-LRx; ION-682884; ION-TTR-LRx; IONIS-TTR-LRx

Latest Information Update: 14 Jan 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ionis Pharmaceuticals
  • Developer Akcea Therapeutics; Ionis Pharmaceuticals
  • Class Antisense oligonucleotides
  • Mechanism of Action Prealbumin expression inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Transthyretin-related hereditary amyloidosis

Most Recent Events

  • 10 Jan 2020 Ionis Pharmaceuticals in collaboration with Akcea Therapeutics initiates enrolment in the phase III CARDIO-TTRansform trial for Transthyretin related hereditary amyloidosis in USA (SC) (NCT04136171)
  • 24 Nov 2019 Phase-III clinical trials in Transthyretin-related hereditary amyloidosis in USA (SC) (NCT04136184)
  • 06 Nov 2019 Ionis Pharmaceuticals plans the phase III CARDIO-TTRansform trial in Transthyretin‑mediated amyloid cardiomyopathy in fourth quarter of 2019 (ION-682884-CS2; EudraCT2019-002835-27; NCT04136171)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top